SLU-PP-322

SLU-PP-322 emerged from Saint Louis University in 2023 as a small-molecule ERR agonist that shifts muscle toward oxidative type-I fiber programming. Mouse studies show increased running endurance and improved glucose handling without weight loss. There is no published human data, and the long-term safety of pan-ERR activation is unknown.

Pan-agonist of estrogen-related receptors (ERRα/β/γ), upregulating mitochondrial biogenesis and oxidative metabolism in skeletal muscle.

• Energy

  Energy & Mitochondrial Output

  Mitochondrial biogenesis lifts oxidative capacity in mice.

  STRENGTH

  72%
• Fat loss

  Fat Loss & Body Composition

  Improved fat oxidation; modest body-comp changes in animals.

  STRENGTH

  60%
• Longevity

  Longevity & Cellular Health

  Mitochondrial uplift is a longevity-aligned mechanism.

  STRENGTH

  55%

No human safety data. Pan-ERR activation could theoretically stress cardiac tissue at high exposures.

• No clinical use; do not use in humans outside controlled research.

Investigational. No human approval anywhere; pre-clinical only.